7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2011-09-30 2011-06-30 2011-03-31 2010-06-30 2008-03-31 
      
    		                                                  
      cash flows from operating activities
    		                                                  
      net income
    		390,895,000 28,187,000 5,060,000 23,331,000 3,880,000 6,879,000 -10,707,000 -14,416,000 113,929,000 -47,609,000 -39,232,000 -52,994,000 -35,818,000 -40,510,000 -69,013,000 -93,338,000 -85,638,000 -78,497,000 -90,628,000 -88,218,000 -87,163,000      -35,156,000  -33,951,000 -44,142,000 -41,529,000  -31,535,652 -28,353,084 -27,727,509  -24,831,027 -15,899,062 -13,848,662           -1,559,474 
      adjustments to reconcile net income to net cash from operating activities:
    		                                                  
      loss on extinguishment of debt
    		   0                                               
      noncash stock compensation expense
    		17,686,000 16,361,000 14,972,000 11,948,000 11,773,000 9,481,000 9,339,000 9,385,000 9,184,000 12,541,000 6,823,000 11,051,000 6,988,000 -975,000 2,121,000 14,356,000 13,996,000 16,304,000 16,618,000 33,521,000 28,330,000    2,075,000 1,757,000 1,882,000 1,458,000 -173,000 4,264,000 7,337,000 3,569,978 4,890,123 1,489,728 5,995,455 1,328,599 2,834,038 1,648,397 1,698,965 2,857,044 1,240,034 6,242,986 5,357,028 5,038,436 4,096,572      
      depreciation and amortization
    		17,000 13,000 8,000 9,000 11,000 19,000 29,000 38,000 73,000 32,000 68,000 73,000 76,000 78,000 76,000 80,000 76,000 67,000 59,000 53,000 41,000 34,000 30,000                            
      amortization of premium (discount) on investment securities
    		-786,000 -1,283,000 -1,336,000  -1,817,000 -1,800,000 -1,670,000 -1,532,000 -217,000 -186,000 -301,000 -159,000                                       
      amortization of debt issuance costs
    		304,000 304,000 304,000 303,000 414,000 639,000 639,000 639,000                 231,000 231,000 77,000                        
      amortization of leasehold interest
    		45,000 46,000 48,000 53,000 53,000 53,000 53,000 53,000                                           
      deferred income taxes
    		                                                  
      noncash change in lease liability and right of use asset
    		431,000 432,000 453,000 498,000 497,000 498,000 407,000 490,000                                           
      change in fair value of equity investments
    		-420,000 181,000 104,000 501,000 75,000 373,000 -195,000                                            
      change in fair value of notes payable
    		14,000 -64,000 213,000 153,000 127,000 59,000 -35,000 184,000 -332,000 202,000 59,000 125,000 35,000 -98,000 -178,000 -263,000 -94,000 -163,000 -58,000 462,000 134,000 172,000 -20,000      -119,000    29,588     -31,752 -58,632 36,805 -113,692 23,154 -2,984 92,046 23,930      
      changes in assets and liabilities:
    		                                                  
      increase in inventory
    		8,695,000 3,595,000 -46,305,000 -24,820,000 -2,540,000 -2,560,000 -36,931,000                                            
      increase in other current assets
    		-30,632,000 -5,260,000 -4,627,000 16,731,000                   -1,057,000     1,783,000 -2,208,000         -3,449,803 -2,250,490 949,345 1,061,924 -957,985 -4,159,055 3,022,889 -5,201,987      
      increase in accounts receivable
    		-33,868,000 -41,395,000 -60,936,000 -13,458,000 -32,119,000 -18,626,000 -13,889,000                                            
      increase in accounts payable and accrued expenses
    		-17,280,000 5,565,000 65,585,000 -38,012,000 11,669,000 8,959,000 40,222,000   9,278,000 9,858,000 16,426,000 -6,081,000 -11,185,000 -10,170,000 3,901,000 8,819,000 2,367,000 904,000 5,738,000   -1,567,000 -958,000   2,240,000 -1,364,000 3,423,000 3,606,000 5,292,000 8,353,870 -401,751 516,189 2,551,726 45,429 2,735,203 5,287,986 -1,575,974 812,787 639,361 -416,046 4,434,813 -3,873,006 6,271,742      
      decrease in lease liabilities
    		-519,000 -518,000 -543,000 -598,000 -597,000 -597,000 -596,000 -595,000                                           
      increase in other current liabilities
    		-277,000 -515,000 -1,855,000 1,178,000 -795,000 611,000 3,035,000 651,000 701,000 704,000 619,000 874,000 -337,000 1,201,000 539,000          22,263,000                          
      increase in deferred revenue
    		9,169,000 1,787,000 140,000 -1,761,000 18,144,000 498,000 602,000 -926,000                                           
      net cash from operating activities
    		-23,153,000 7,436,000 -28,715,000 -25,641,000 -12,205,000 5,536,000 -8,207,000 -13,210,000 83,704,000 -42,005,000 -59,902,000 -23,870,000 -34,495,000 -49,116,000 -68,689,000 -86,909,000 -67,201,000 -60,169,000 -81,355,000 -52,026,000 -56,532,000 -43,834,000 -62,115,000 -30,393,000   -33,351,000 -33,690,000 -33,009,000 -34,183,000 -28,043,000 -21,855,129 -22,776,473 -26,829,596 -22,302,364 -17,025,067 -15,042,201 -12,850,521 -16,673,541 -12,900,661 -10,658,732 -12,248,526 -8,882,353 -15,106,938 -8,050,975    445,987 -1,461,625 
      capex
    		-80,000 -42,000 -25,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -175,000 -67,000 -155,000 -89,000 -45,000 -68,000 -34,000   -14,000 0 0 -34,000 -24,000 0 0 0 0 -20,970 0 -27,795 -282,261 16,977 0 -13,397 -6,883 -14,072 -1,333    0 0 
      free cash flows
    		-23,233,000 7,394,000 -28,740,000 -25,641,000 -12,205,000 5,536,000 -8,207,000 -13,210,000 83,704,000 -42,005,000 -59,902,000 -23,870,000 -34,495,000 -49,116,000 -68,689,000 -86,909,000 -67,201,000 -60,344,000 -81,422,000 -52,181,000 -56,621,000 -43,879,000 -62,183,000 -30,427,000   -33,365,000 -33,690,000 -33,009,000 -34,217,000 -28,067,000 -21,855,129 -22,776,473 -26,829,596 -22,302,364 -17,046,037 -15,042,201 -12,878,316 -16,955,802 -12,883,684 -10,658,732 -12,261,923 -8,889,236 -15,121,010 -8,052,308    445,987 -1,461,625 
      cash flows from investing activities
    		                                                  
      proceeds from maturity of held-to-maturity securities
    		77,750,000                                                  
      investment in held-to-maturity securities
    		-31,307,000 -53,300,000 -92,059,000 -57,891,000 -101,360,000 -69,734,000 -81,531,000 -68,433,000 -56,279,000 0 -22,168,000 -3,998,000 -31,466,000 -14,921,000 -56,889,000 -12,232,000 -11,802,000 -14,050,000 -17,447,000 -59,921,000 0 0 -7,482,000    -8,171,000 -6,656,000 -17,609,000 -2,781,000 -4,184,000     0 0 -4,558,652 -10,641,270 -8,038,515           
      investment in equity investments
    		0                                                  
      purchases of property, plant and equipment
    		-80,000 -42,000 -25,000                              0     -27,795 -282,261 16,977           
      net cash from investing activities
    		46,363,000 -3,992,000 -12,934,000 15,788,000 -9,334,000 1,765,000 -9,255,000 -44,755,000 -30,229,000 30,501,000 -6,168,000 16,269,000 -2,990,000 10,379,000 -43,671,000 3,288,000 -631,000 -2,475,000 -514,000 -52,076,000 14,911,000 11,205,000 1,450,000 4,000   -1,135,000 238,000 -6,435,000 5,585,000 1,792,000 -28,006,270 8,800,000 4,997,773 6,000,000 11,479,030 15,576,260 1,413,553 -1,923,531 2,478,462 76,574 -31,084,022 3,843,117 -9,132,783 -1,333    530,141 -13,620 
      cash flows from financing activities
    		                                                  
      payment of loan payable
    		   0                                               
      proceeds from exercise of options
    		0 432,000 21,000 570,000 199,000 135,000 10,000 0               81,000                            
      proceeds from debt financings
    		   0    0                 -4,000 -61,000 29,740,000                        
      financing costs paid
    		   -31,000    0 0 0 -125,000             -315,000   -538,000                        
      purchase of treasury stock
    		-78,242,000 -6,875,000 -6,123,000 -6,611,000                                               
      net cash from financing activities
    		-78,242,000 -6,443,000 -6,102,000 -6,072,000 134,454,000 135,000 10,000 -1,000 421,000 47,047,000 25,238,000 49,000 275,000 135,000 -850,000 55,997,000 -7,361,000 -7,162,000 -55,000 403,389,000 35,265,000 241,092,000 81,000 98,354,000 20,695,000 28,284,000 56,880,000 4,694,000 4,492,000 52,023,000 52,430,000 14,737,079 28,216,277 3,796,614 86,908,656 1,420,796 44,630 3,536,380 14,163 21,588 15,744,012 17,628,189 35,329,897 26,727,706 24,200,130    94,469 1,958,683 
      net increase in cash, cash equivalents and restricted cash
    		   -15,925,000       -40,832,000     -27,624,000 -75,193,000   299,287,000 -6,356,000 208,463,000 -60,584,000 67,965,000 -12,551,000 -7,119,000 22,394,000 -28,758,000 -34,952,000 23,425,000 26,179,000                    
      cash, cash equivalents and restricted cash at beginning of period
    		0 0 181,192,000 0 0 0 94,218,000 0 0 0 103,577,000 0 0 0 300,151,000 0 0 0 554,698,000  0 1,000 113,887,000  0 0 43,199,000  0 0 57,305,000                    
      cash, cash equivalents and restricted cash at end of period
    		-55,032,000 -2,999,000 133,441,000 -15,925,000 112,915,000 7,436,000 76,766,000 -57,966,000 53,896,000 35,543,000 62,745,000 -7,552,000 -37,210,000 -38,602,000 186,941,000 -27,624,000 -75,193,000 -69,806,000 472,774,000  -6,356,000 208,464,000 53,303,000  -12,551,000 -7,119,000 65,593,000  -34,952,000 23,425,000 83,484,000                    
      reconciliation to amounts on condensed consolidated balance sheets:
    		                                                  
      cash and cash equivalents
    		-55,045,000 -3,013,000 132,139,000 -15,928,000 112,912,000 7,433,000 75,477,000 -57,969,000 53,893,000 35,540,000 61,469,000 -7,556,000 -37,213,000 -38,603,000 185,676,000 -27,625,000 -75,195,000 -69,807,000 471,514,000 299,285,000 -6,358,000 208,461,000 52,051,000 67,962,000 -12,553,000 -7,121,000 64,349,000 -28,760,000 -34,954,000 22,776,000 82,896,000                    
      restricted cash
    		13,000 14,000 1,302,000 3,000 3,000 3,000 1,289,000 3,000 3,000 3,000 1,276,000 4,000 3,000 1,000 1,265,000 1,000 2,000 1,000 1,260,000 2,000 2,000 3,000 1,252,000 3,000 2,000 2,000 1,244,000 2,000 2,000 649,000 588,000                    
      total cash, cash equivalents and restricted cash
    		-55,032,000 -2,999,000 133,441,000 -15,925,000 112,915,000 7,436,000 76,766,000 -57,966,000 53,896,000 35,543,000 62,745,000 -7,552,000 -37,210,000 -38,602,000 186,941,000 -27,624,000 -75,193,000 -69,806,000 472,774,000 299,287,000 -6,356,000 208,464,000 53,303,000 67,965,000 -12,551,000 -7,119,000 65,593,000 -28,758,000 -34,952,000 23,425,000 83,484,000                    
      cash paid for:
    		                                                  
      interest
    		6,099,000 6,097,000 6,143,000 6,422,000 7,112,000 2,488,000 2,448,000 2,433,000 2,409,000 2,180,000 1,749,000 1,537,000 1,286,000 1,038,000 1,584,000 768,000 604,000 1,325,000 769,000 1,054,000 1,892,000 778,000 777,000                            
      income taxes
    		1,957,000                                                  
      ​
    		                                                  
      net decrease in cash, cash equivalents and restricted cash
    		 -2,999,000 -47,751,000   7,436,000 -17,452,000      -37,210,000 -38,602,000 -113,210,000    -81,924,000                                
      proceeds from maturity of short-term securities
    		  80,400,000 73,700,000 92,300,000 71,499,000 73,401,000 23,678,000 26,050,000 30,501,000 16,000,000 20,270,000 28,480,000 25,300,000 13,225,000 15,600,000 11,250,000 11,750,000 17,000,000 8,000,000 15,000,000 11,250,000 9,000,000 6,750,000 9,000,000 6,450,000 7,050,000 6,900,000 11,200,000 8,400,000 6,000,000 0 8,800,000 5,000,000 6,000,000 11,500,000 3,000,000 6,000,000 9,000,000 10,500,000 6,000,000 4,000,000 3,850,000        
      investment in long-term securities
    		  -1,250,000 0 -250,000 0 -1,125,000                                            
      amortization of discount on investment securities
    		                                                  
      purchases of ppe
    		           -3,000 -4,000 0 -7,000 -80,000                                   
      proceeds from sale of common stock
    		                       98,357,000 20,699,000 28,287,000 27,678,000 4,694,000 4,492,000 52,023,000 52,430,000 14,737,079 28,216,275 3,796,615 84,765,572 906,972 0   0 15,775,638 17,043,830 34,941,049 26,056,167 22,766,685      
      reconciliation to amounts on consolidated balance sheets:
    		                                                  
      noncash transactions
    		                                                  
      deferred financing costs
    		       0 0               0 0 -169,000 1,157,000                        
      warrants issued with debt financing
    		       0 0               0 0 0 993,000                        
      issuance of common stock
    		                                                  
      decrease (increase) in other current assets
    		     1,050,000 1,490,000                                            
      decrease (increase) in accounts receivable
    		                                                  
      decrease in accounts payable and accrued expenses
    		                                             -39,930 24,369 -40,236   
      decrease in deferred revenue
    		         -38,000 -38,000 -38,000 -38,000 -38,000 -38,000 -38,000 -38,000 -38,000 -38,000 -38,000 -38,000 -38,000 -38,000 -38,000   -38,000 -38,000 -38,000 -38,000 -38,000 -38,095 -38,095 -38,096 -38,095 -38,095 -38,095 -38,095 -38,096 -38,095 -38,095 -38,096 -38,095 -38,095 -38,095      
      offering costs paid
    		                -21,000 0 -183,000                                
      amortization of premium on investment securities
    		             -40,000 23,000 96,000 139,000 155,000 127,000 45,000 -6,000 -25,000 -44,000 -48,000   -75,000 -68,000 -42,000 -11,000 2,000 7,460 8,930 14,402 30,528 91,756 113,541 125,803 128,329 158,372 172,361 124,812 80,597 66,321 60,317      
      shares issued in connection with in-licensing agreement
    		                                                  
      shares issued in connection with in-licensing
    		                       0                           
      decrease in other current liabilities
    		                          -559,000                        
      decrease in other liabilities
    		                 -146,000 -3,717,000    -18,898,000                            
      purchases of equipment
    		                 -175,000 -67,000 -155,000 -89,000 -45,000 -68,000 -34,000   -14,000   -34,000 -24,000     -20,970      -13,397 -6,883 -14,072 -1,333      
      increase in accrued interest receivable
    		                                       -27,494 31,786 -100,603 -4,194 -31,695 20,861      
      increase in lease liabilities
    		                                                  
      increase in interest payable
    		                        344,000 -106,000 549,000                 0 0 277,328 285,724 280,509   
      increase in other liabilities
    		                   -3,679,000 -4,319,000                              
      cash, cash equivalents and restricted cash at beginning of year
    		                                                  
      cash, cash equivalents and restricted cash at end of year
    		                                                  
      noncash licensing expense
    		                        0    0                      
      noncash change in lease liability and right-of-use asset
    		                                                  
      decrease in other current assets
    		                                                  
      decrease in accrued interest receivable
    		                      40,000    14,000  6,000 -8,000 30,000    61,028                
      investment in short-term securities
    		                                                  
      decrease in leasehold interest
    		                         45,000 46,000  45,000 20,000 33,000                    
      decrease (increase) in accrued interest receivable
    		                                   24,606 25,308 30,340 21,915            
      accrued offering costs
    		                         -119,000 179,000        190,709                
      consolidated net income
    		                      -51,116,000                 -17,611,812 -13,655,916 -17,103,183 -14,577,735  -17,451,169      
      non-cash stock compensation expense
    		                      11,068,000                            
      non-cash change in lease liability and right-of-use asset
    		                         529,000 373,000                        
      adjustments to reconcile consolidated net income to net cash from operating activities:
    		                                                  
      change in fair value of notes payable and accrued interest
    		                       96,000 -50,000 12,000 66,000    96,000    105,782 -45,835               
      decrease in other assets
    		                                  242,372    5,341    25,913        
      increase in deferred rent
    		                           26,000 25,000 23,000 23,000 31,401 28,364 22,289 22,289 22,289 112,248              
      proceeds from the exercise of warrants
    		                               0 2 -1 2,143,084 517,346 50,625 28,108 22,163 57,354 17,341 584,358 408,286 666,319 1,288,245      
      reclassification of deferred financing costs to additional paid-in capital
    		                                       -48,022 -15,017          
      cash flows from operating activities:
    		                                                  
      depreciation
    		                        26,000 23,000 23,000  23,000 21,000 20,000  20,939 20,654 20,416 20,496 19,145 16,939 6,380 5,126 4,521 3,386 2,419 1,477 896 236 411 757 -5,529 7,912 
      decrease (increase) in prepaid research and development and other current assets
    		                        1,563,000      691,000                    
      decrease in lease liability
    		                          -339,000                        
      cash flows from investing activities:
    		                                                  
      cash flows from financing activities:
    		                                                  
      noncash transactions:
    		                                                  
      shares to be issued in connection with in-licensing
    		                                                  
      increase in prepaid research and development and other current assets
    		                          -2,454,000        -3,584,938                
      gain on sale of long-term securities
    		                                   0               
      decrease (increase) in leasehold interest
    		                               36,768 13,147 55,445 19,587                
      decrease (increase) in other assets
    		                               0                   
      proceeds from the sale of long-term securities
    		                                   0               
      deferred financing costs paid
    		                                         1 -19,438        
      reclassification of deferred financing costs to additional paid-in capital
    		                               0 0 0 -2,645 31,891 0              
      conversion of convertible notes payable to common stock
    		                                   2,416 0              
      accrued financing cost
    		                                                  
      increase in restricted cash
    		                               -1,032 -1,030 -1,016 -1,005 -1,024 -1,023 -1,010 -1,008 -1,017 -1,016 -1,038 -1,060        
      net increase in cash and cash equivalents
    		                               -35,124,320 14,239,804 -18,035,209 70,606,292 -4,125,241 578,689 -7,900,588 -18,582,909 -10,400,611 5,161,854 -25,704,359 30,290,661 2,487,985  -280,228 -98,808 112,648 1,070,597 483,438 
      cash and cash equivalents at beginning of year
    		                                                  
      cash and cash equivalents at end of year
    		                                                  
      financing costs
    		                                    -5,995 4,011 -8,000            
      cash and cash equivalents at beginning of period
    		                                0 0 25,031,280  0 0 55,061,329  0 0 55,713,784  0 0 0 478,668 -631,690 649,686 
      cash and cash equivalents at end of period
    		                                14,239,804 -18,035,209 95,637,572  578,689 -7,900,588 36,478,420  5,161,854 -25,704,359 86,004,445  16,147,822 -280,228 -98,808 591,316 438,907 1,133,124 
      increase in other assets
    		                                   -1,261 5,995              
      accrued financing costs
    		                                                  
      gain on settlement of notes payable
    		                                            0      
      noncash stock expense associated with in-licensing agreements
    		                                           0       
      increase in leasehold interest
    		                                   475,490 -549,037              
      decrease in interest payable
    		                                                  
      proceeds from the exercise of options
    		                                           57,200       
      payment of notes payable
    		                                           0 0      
      deferred rent
    		                                      389,554            
      increase in prepaid rent
    		                                      -1,151,163            
      impairment of in-process research and development
    		                                                  
      noncash stock expense associated with in-licensing agreement
    		                                                  
      investment in held-to-maturity long-term securities
    		                                                  
      investment in held-to-maturity short-term securities
    		                                           -9,118,711 -6,127,539      
      changes in assets and liabilities, net of effects of acquisition:
    		                                                  
      gain on settlement of note payable
    		                                                  
      net decrease in cash and cash equivalents
    		                                                  
      stock compensation expense
    		                                                  
      cash acquired in connection with acquisition
    		                                                  
      payments of short-term loans
    		                                                  
      proceeds from sale of preferred stock
    		                                                  
      conversion of notes payable to preferred stock
    		                                                  
      net income/
    		                                             -551,739 -2,982,539 3,832,383   
      adjustments to reconcile net income/(loss) to net cash from operating activities:
    		                                                  
      equity in losses of hedrin jv
    		                                                  
      non cash gain on nordic settlement
    		                                             0 0 -4,017,488   
      share-based compensation
    		                                             5,597 5,536 8,077 13,287 192,854 
      amortization of oid, issue costs and beneficial conversion feature
    		                                             887,198     
      change in fair value of derivative liability
    		                                             -2,100,898 2,231,746 -170,435   
      loss on early extinguishment of debt
    		                                                  
      shares issued in connection with ariston milestone
    		                                             0 0 220,701   
      warrants issued to consultant
    		                                                  
      amortization of intangible assets
    		                                                  
      gain on sale of marketable equity securities
    		                                                  
      noncash portion of in-process research and development charge
    		                                                  
      loss on impairment and disposition of intangible assets
    		                                                  
      other
    		                                                  
      changes in operating assets and liabilities, net of acquisitions:
    		                                                  
      decrease in grant receivable
    		                                             0     
      decrease in prepaid expenses and other current assets
    		                                             16,068     
      decrease/(increase) in other assets
    		                                             0 0 10,859   
      purchase of property and equipment
    		                                                  
      cash acquired in connection with acquisitions
    		                                                  
      net cash provided from the purchase and sale of short-term investments
    		                                                  
      proceeds from sale of license
    		                                                  
      proceeds related to sale of common stock
    		                                                  
      proceeds from the hedrin jv agreement
    		                                                  
      proceeds from sale of notes payable
    		                                                  
      sale of warrant
    		                                                  
      net repayments of notes payable
    		                                             0 0 -100,000   
      net cash provided by/(used in) financing activities
    		                                             0 0 -100,000   
      adjustments to reconcile net income/(loss) to net cash provided by/(used in) operating activities:
    		                                                  
      net cash provided by/(used in) operating activities
    		                                              -98,808 212,648   
      amortization of oid and issue costs
    		                                               12,062   
      increase in grant receivable
    		                                                  
      increase in prepaid expenses and other current assets
    		                                               75,459   
      amortization of oid and issue costs on secured 12% notes
    		                                                  
      decrease in restricted cash
    		                                                  
      decrease/(increase) in prepaid expenses and other current assets
    		                                                  
      increase/(decrease) in accounts payable and accrued expenses
    		                                                  
      increase in interest payable, current portion
    		                                                  
      increase in interest payable, noncurrent portion
    		                                                  
      repayments of notes payable
    		                                                  
      proceeds from exercise of warrants and stock options and sale of warrant
    		                                                  
      interest and amortization of oid and issue costs
    		                                                  
      change in fair value of derivative
    		                                                  
      non-cash portion of in-process research and development charge
    		                                                  
      decrease (increase) in prepaid expenses and other current assets
    		                                                  
      proceeds from sale of secured 12% notes
    		                                                  
      proceeds from sale of convertible 12% notes
    		                                                  
      proceeds from 8% note
    		                                                  
      repayment of 8% note
    		                                                  
      proceeds from (repayments of) notes payable
    		                                                  
      repayment of secured 10% notes
    		                                                  
      non cash portion of in-process research and development charge
    		                                                  
      (increase)/decrease in prepaid expenses
    		                                                 -17,693 
      increase /(decrease) in accounts payable
    		                                                 -293,262 
      increase in accrued expenses
    		                                                 208,038 
      cash paid in connection with acquisitions
    		                                                  
      proceeds from the sale of license
    		                                                  
      investment in hedrin jv’s general partner
    		                                                 -13,620 
      repayments of notes payable to stockholders
    		                                                  
      proceeds from exercise of warrants and stock options
    		                                                  
      proceeds from the put and warrant issued in the hedrin jv
    		                                                 1,958,683 
      supplemental disclosure of cash flow information:
    		                                                  
      interest paid
    		                                                  
      supplemental disclosure of noncash investing and financing activities:
    		                                                  
      common stock issued in satisfaction of accounts payable
    		                                                  
      imputed preferred stock dividend
    		                                                  
      preferred stock dividends accrued
    		                                                  
      preferred stock dividends paid by issuance of shares
    		                                                  
      conversion of preferred stock to common stock
    		                                                  
      issuance of common stock for acquisitions
    		                                                  
      issuance of common stock in connection with in-licensing agreement
    		                                                  
      marketable equity securities received in connection with sale of license
    		                                                  
      net liabilities assumed over assets acquired in business combination
    		                                                  
      cashless exercise of warrants
    		                                                  
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.